Boehringer Ingelheim's Spiriva Respimat available in the US
Boehringer Ingelheim’s Spiriva Respimat is now available for the treatment of asthma by prescription in US pharmacies. The US Food and Drug Administration (FDA) approved a once-daily dose of 2.5 µg for the long-term maintenance treatment of asthma in people ages 12 and older.
Click on this link for more information.
